Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Achondroplasia.

William A Horton1, Judith G Hall2, Jacqueline T Hecht3

  • 1Research Center, Shriners Hospital for Children and Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA.

Lancet (London, England)
|July 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive analysis of <i>de novo</i> variants across 2,497 orofacial cleft trios reveals novel genetic drivers of disease.

medRxiv : the preprint server for health sciences·2026
Same author

Antisense Reduction of Mutant COMP Reduces Growth Plate Chondrocyte Pathology.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Evaluating the impact of vosoritide on complications of achondroplasia.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Trio-based GWAS reveals novel loci associated with different forms of isolated cleft lip.

medRxiv : the preprint server for health sciences·2026
Same author

Is 7p14.1 an orofacial cleft risk locus? Genome-wide study of copy number variation in multiple populations provides both a replication of previous studies and an alternative explanation.

medRxiv : the preprint server for health sciences·2026
Same author

Distinguishing syndromic and nonsyndromic cleft palate through analysis of protein-altering de novo variants in 818 trios.

American journal of human genetics·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Achondroplasia, a common dwarfism, stems from a specific mutation in fibroblast growth factor receptor 3 (FGFR3). Understanding this genetic cause aids in developing targeted therapies for skeletal growth disorders.

Area of Science:

  • Genetics and Molecular Biology
  • Skeletal Dysplasias
  • Developmental Biology

Background:

  • Achondroplasia is the most prevalent form of short limb dwarfism, impacting over 250,000 individuals globally.
  • A specific point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene is identified in over 95% of patients, with most being de novo mutations.
  • This mutation leads to enhanced FGFR3 function, significantly affecting the cartilaginous growth plate and causing characteristic skeletal manifestations.

Purpose of the Study:

  • To elucidate the biology of FGFR3 and the molecular consequences of the achondroplasia mutation.
  • To provide a comprehensive understanding of the disorder for the development of targeted treatments.
  • To further define the natural history of achondroplasia in adults and identify strategies for complication management.

Related Experiment Videos

Main Methods:

  • Review and synthesis of current research on FGFR3 biology and achondroplasia pathogenesis.
  • Analysis of genetic data regarding mutation prevalence and origins.
  • Examination of clinical data on the natural history and complications of achondroplasia.

Main Results:

  • The achondroplasia mutation results in a gain of function in FGFR3, impacting skeletal development.
  • Understanding the molecular pathways downstream of FGFR3 provides a basis for novel therapeutic strategies.
  • Early detection and intervention can favorably modify or prevent serious complications associated with achondroplasia.

Conclusions:

  • Continued research into FGFR3 signaling pathways is crucial for developing effective treatments for achondroplasia.
  • Targeted therapies aimed at inhibiting aberrant FGFR3 signaling or modulating downstream pathways show promise.
  • Comprehensive management, including early intervention, is key to improving outcomes for individuals with achondroplasia.